| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-05-15 | Cytos Biotechnology (Switzerland) | CHF 37 million (€30.6 milion) | equity and debt | international syndicate of five strategic investors including Amgen (USA), Abingworth (UK), Aisling Capital (USA) and venBio (USA) | Allergic diseases - Inflammatory diseases - Respiratory diseases | Fundraising |
| 2012-05-15 | Gamida Cells (Israel) | $10 Million | financing round | Cancer - Oncology | Fundraising | |
| 2012-05-14 | Intercell (Austria) | € 25 million | loan - private placement | BB Biotech (Switzerland) Novartis (Switzerland) healthcare and institutional investors |
Infectious diseases | Fundraising |
| 2012-05-08 | Prophylix Pharma (Norway) | up to € 6 million | grant | Immunological diseases | Grant | |
| 2012-05-08 | Lanthio Pharma (The Netherlands) | €176,000 | grant | SNN (The Netherlands) - Province of Groningen (The Netherlands) | Technology - Services | Grant |
| 2012-05-08 | Oramed Pharmaceuticals (Israel) | NIS 2 million (approximately $540,000 or €414,000) | grant | Office of the Chief Scientist (OCS -Israel) | Metabolic diseases | Grant |
| 2012-05-03 | iTeos Therapeutics (Belgium) | €9 million | series A equity financing round | Sopartec - VIVES-Louvain Technology Fund (Belgium) Life Sciences Research Partners (Belgium) Hunza Ventures SCA (Belgium) business angels |
Cancer - Oncology | Fundraising |
| 2012-05-02 | Ark Therapeutics (UK) | up to €6 million | grant | Grant | ||
| 2012-05-02 | Galecto Biotech (Sweden) | financing round | Sunstone Capital (Denmark) - SEED Capital (Denmark) | Inflammatory diseases - Fibrosis | Fundraising | |
| 2012-04-30 | Pluristem Therapeutics (Israel) | 11.8 million New Israeli Shekels (approximately $3.1 million) | grant | Office of the Chief Scientist (OCS) | Cardiovascular diseases - Regenerative medicine | Grant |
| 2012-04-27 | ReNeuron (UK) | £5.4 million (€6.6 million) + £0.7 million (€0.85 million) | private placement and open offer | Cardiovascular diseases - Regenerative medicine | Private placement | |
| 2012-04-26 | Innovacell (Austria) | € 8.3 million | Buschier (Switzerland) Fides (Austria) HYBAG (Switzerland) uni venture |
Regenerative medicine | Fundraising | |
| 2012-04-17 | Imaxio (France) | €2.9 million | financing round | Pradeyrol Développement (France) | Cancer - Oncology - Infectious diseases | Fundraising |
| 2012-04-17 | to-BBB (The Netherlands) | grant | The Michael J. Fox Foundation - MJFF (USA) | Neurodegenerative diseases | Grant | |
| 2012-04-17 | Sensorion (France) | €0.75 million | Innobio (France) | Otorhinolaryngology | Fundraising | |
| 2012-04-12 | Aleva Neurotherapeutics (Switzerland) | CHF 4 million (€3.22 million) | series B financing round | Banexi Ventures Partners BioMedInvest AG BB BIOTECH VENTURES III, L.P Initiative Capital Romandie (Switzerland |
Neurodegenerative diseases - CNS diseases | Fundraising |
| 2012-04-05 | Galapagos (Belgium) | €1,099,662.27 | capital increase arising from employee warrant exercises | Galapagos' employees |
Technology - Services | Capital increase |
| 2012-04-05 | Newron (Italy) | €20 million | equity investment | Zambon (Italy) | Neurodegenerative diseases | Fundraising |
| 2012-04-04 | BioInvent International (Sweden) | SEK 104,8 million (€11.9 million) | private placement | Cancer - Oncology | Private placement | |
| 2012-04-04 | Summit Corporation (UK) | £5.0 million before expenses (€6.4 million before expenses) | private placement of new ordinary shares The Placing is conditional upon the Resolutions having passed at the General Meeting to be held on 20 April. The New Ordinary Shares will, when issued and admission is expected to take place and dealing in the New Ordinary Shares on AIM on 24 April 2012. |
Rare diseases - Neuromuscular diseases - Infectious diseases | Private placement |
